Atlas Trials

Cisplatin, Gemcitabine Hydrochloride, and Sorafenib Tosylate in Treating Patients With Transitional Cell Cancer of the Bladder

Clinical trial NCT01222676 · UNKNOWN

Trial details

NCT number
NCT01222676
Sponsor
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Bladder Cancer
Start date
2010-10-01
Primary completion
2013-10-01
Enrollment
45

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.